US Bancorp
YMAB

US Bancorp’s Y-mAbs Therapeutics YMAB Stock Holding History

US Bancorp’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23
Closed -$180 – 4379
2024
Q4 		$180 Buy
23
+6
+35% +$73 ﹤0.01% 4090
2024
Q3 		$224 Buy
+17
New +$215 ﹤0.01% 4008
2022
Q1 		– Sell
-1,313
Closed -$21K – 4223
2021
Q4 		$21K Buy
+1,313
New +$28.1K ﹤0.01% 3100
2021
Q2 		– Sell
-243
Closed -$7K – 4088
2021
Q1 		$7K Sell
243
-222
-48% -$9.1K ﹤0.01% 3430
2020
Q4 		$23K Buy
465
+222
+91% +$10.3K ﹤0.01% 2862
2020
Q3 		$9K Hold
243
– – ﹤0.01% 3131
2020
Q2 		$10K Buy
+243
New +$9.19K ﹤0.01% 3111

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

US Bancorp's YMAB Position: Q1 2025 in Review

US Bancorp sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 23 shares — an estimated $180 sold.

US Bancorp first reported a position in YMAB in Q2 2020 and held it in 7 quarters. The position peaked at $23K in Q4 2020. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • US Bancorp reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • US Bancorp sold 23 Y-mAbs Therapeutics shares in Q1 2025, an estimated $180.
  • US Bancorp first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 7 quarters.
  • US Bancorp's Y-mAbs Therapeutics position peaked at $23K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.